Clinical Trials Logo

Angioplasty clinical trials

View clinical trials related to Angioplasty.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03060460 Terminated - Ultrasound Clinical Trials

Ultrasound Guided Insertion of Sheath Before Angiography or Angioplasty

ACCESS-II
Start date: April 26, 2017
Phase: N/A
Study type: Interventional

The study evaluates whether routine use of ultrasound for sheath insertion during radial or femoral angiography or angioplasty has any impact on: number of punctures, patient discomfort, procedural length, successfull procedure or ideal vessel puncture.

NCT ID: NCT01312935 Terminated - Clinical trials for Percutaneous Coronary Intervention

Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)

Start date: April 2011
Phase: Phase 2
Study type: Interventional

The study investigates the safety and efficacy of PMX-60056 for the Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)

NCT ID: NCT00437905 Terminated - Atherosclerosis Clinical Trials

Balloon Angioplasty vs. Cutting Balloon Angioplasty of Femoropopliteal Arteries- a Randomized Controlled Trial

Start date: June 2003
Phase: Phase 4
Study type: Interventional

The purpose of this study to compare balloon angioplasty (PTA) vs. cutting balloon angioplasty (CB-PTA) in terms of patency and postintervention inflammation in peripheral artery disease.

NCT ID: NCT00289601 Terminated - Angioplasty Clinical Trials

Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty

Start date: March 2006
Phase: Phase 4
Study type: Interventional

This study is a randomized, double-blind, multi-center study designed to compare differences in rates of myonecrosis (measured as an elevation of CK-MB ratio ≥ 2 times ULN) within 24 hours following low-medium risk percutaneous coronary intervention (PCI) in aspirin or clopidogrel non-responsive patients who are randomized to heparin with or without eptifibatide therapy during PCI. The primary objective of this study is to determine if the use of eptifibatide is associated with a significant difference in post-PCI myonecrosis (measured as an elevation of CK-MB ratio ≥ 2 times upper limit of normal [ULN]) within 24 hours of low-medium risk PCI in patients who are aspirin or non-responsive as determined by VerifyNow Aspirin and P2Y12 testing.